This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zelefsky, M. J. Articles by Leibel, S. A. Search for Related Content PubMed PubMed Citation Articles by Zelefsky, M. J. Articles by Leibel, S. A. Social Bookmarking                            What's this?

Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer

From the Department of Radiation Oncology, Solid Tumor Service, Department of Medical Oncology, Department of Nursing, Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Michael J. Zelefsky, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10024; email zelefskm{at}mskcc.org

PURPOSE: To assess the feasibility and tolerance of neoadjuvant and concomitant estramustine phosphate and vinblastine (EV) with high-dose three-dimensional conformal radiotherapy (3D-CRT) for patients with unfavorable-risk prostate cancer.

PATIENTS AND METHODS: Twenty-seven patients with unfavorable-risk prostate cancer were enrolled onto a prospective study to determine the feasibility of combining EV with 3D-CRT. Patients were eligible if any of the following requirements were satisfied: (1) Gleason score 8 and prostate-specific antigen (PSA) > 10 ng/mL; (2) Gleason score of 7 and PSA > 20 ng/mL; (3) clinical stage T3N0M0 disease with PSA > 20 ng/mL; (4) any patient with T4N0M0 disease; or (5) patients with TXN1MO disease. Therapy consisted of three 8-week cycles of EV and 8 weeks of 3D-CRT. Estramustine phosphate was given orally beginning on week 1 and continued until the completion of 3D-CRT. Each 8-week cycle of vinblastine consisted of 6 weekly intravenous injections followed by a 2-week rest period. Radiation therapy was administered using a three-dimensional conformal approach to a prescription dose of 75.6 Gy. The median follow-up was 26 months (range, 6 to 40 months).

RESULTS: Twenty-three (85%) of 27 patients completed the entire course of therapy and were assessable for toxicities and biochemical outcome. Two patients (7%) developed grade 3 hematologic toxicity that resolved, and two patients (7%) developed grade 3 hepatoxicity, manifesting as persistent elevation of serum transaminase levels, necessitating discontinuation of the chemotherapy and withdrawal from the treatment program. The most prominent adverse effects from this regimen were mild to moderate (grade 1 to 2) nausea and fatigue related to estramustine. Mild peripheral edema was seen in 15% of patients and was treated with diuresis. 3D-CRT was tolerated well in these patients. Medications were required for relief of acute grade 2 rectal (gastrointestinal [GI]) and urinary (genitourinary [GU]) symptoms in 35% and 48% of patients, respectively. Three patients developed acute grade 3 GU toxicities. The 2-year actuarial likelihood of late grade 2 GI toxicity was 20%. No late grade 3 or 4 GI toxicities were observed. The 2-year actuarial likelihoods of late grade 2 and 3 GU toxicities were 25% and 12%, respectively. No grade 4 GU toxicity was observed.

CONCLUSION: Neoadjuvant and concomitant EV with high-dose 3D-CRT is well tolerated in patients with unfavorable-risk prostate cancer. Although the incidence of modest (grade 2) late GI and GU toxicities seem to be increased compared with 3D-CRT alone or in combination with androgen ablation therapy, no severe toxicities were encountered with this regimen.

Presented at the Thirty-Third Annual Meeting of the American Society of Clinical Oncology, Denver, CO, May 17-20, 1997.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. J. Sanfilippo, S. S. Taneja, A. Chachoua, H. Lepor, and S. C. Formenti Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2973 - 2978. [Abstract] [Full Text] [PDF]

				M. Gleave and W. K. Kelly High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy J. Clin. Oncol., November 10, 2005; 23(32): 8186 - 8191. [Abstract] [Full Text] [PDF]

				P. G. Febbo, J. P. Richie, D. J. George, M. Loda, J. Manola, S. Shankar, A. Szot Barnes, C. Tempany, W. Catalona, P. W. Kantoff, et al. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5233 - 5240. [Abstract] [Full Text] [PDF]

				P. Kumar, M. Perrotti, R. Weiss, M. Todd, S. Goodin, K. Cummings, and R. S. DiPaola Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate J. Clin. Oncol., May 15, 2004; 22(10): 1909 - 1915. [Abstract] [Full Text] [PDF]

				W. K. Kelly, A. X. Zhu, H. Scher, T. Curley, M. Fallon, S. Slovin, L. Schwartz, S. Larson, W. Tong, B. Hartley-Asp, et al. Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2098 - 2107. [Abstract] [Full Text] [PDF]